Company Encyclopedia
View More
name
Predictive Oncology
POAI.US
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development.
1.380 T
POAI.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking111/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE224.27%A
    • Profit Margin-5066.96%E
    • Gross Margin-130.96%E
  • Growth ScoreB
    • Revenue YoY320.71%A
    • Net Profit YoY-503.68%E
    • Total Assets YoY-58.16%E
    • Net Assets YoY-4036.41%E
  • Cash ScoreB
    • Cash Flow Margin-1.97%D
    • OCF YoY320.71%A
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreE
    • Gearing Ratio2567.98%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Predictive Oncology Amends Bylaws to Reflect Name Change to Axe Compute

    Predictive Oncology Inc. has amended its bylaws to change its corporate name to Axe Compute Inc., effective December 11, 2025. The amendments reflect the new name and integrate prior changes without other substantive modifications. This information was published via EDGAR by Predictive Oncology Inc.

    Reuters·
    US
    POAI
    0.00%
    US
    AGPU
    0.00%
    Reuters·
    US
    POAI
    0.00%
    US
    AGPU
    0.00%

    U.S. Stock Market Midday Update: Predictive Oncology surges 15.10%, trading volume spikes, market volatility raises concerns

    Predictive Oncology rose 15.10%; Boston Scientific fell 0.81%, with a trading volume of USD 384 million; Intuitive Surgical fell 0.95%, with a trading volume of USD 210 million; Teleflex rose 10.23%, with a trading volume of USD 156 million; Abbott fell 0.06%, with a market capitalization of USD 212.2 billion

    Tracking Unusual Activity·
    US
    POAI
    0.00%
    US
    AGPU
    0.00%
    Tracking Unusual Activity·
    US
    POAI
    0.00%
    US
    AGPU
    0.00%

    Healthcare Names Post Strong After-Hours Moves: KYMR, OCUL, POAI Among Top Gainers

    Several healthcare and biotech stocks, including Kymera Therapeutics, Ocular Therapeutix, and Predictive Oncology, posted significant gains in Friday's after-hours trading. The momentum was driven by clinical updates, recent announcements, and technical rebounds. Kymera surged 9.58% due to anticipation of clinical trial results, while Predictive Oncology rebounded 13.62% after regaining Nasdaq compliance.

    rttnews·
    US
    KYMR
    +2.13%
    US
    OCUL
    -0.75%
    US
    POAI
    0.00%
    rttnews·
    US
    KYMR
    +2.13%
    US
    OCUL
    -0.75%
    US
    POAI
    0.00%

    Chmn Vennare Acquires 5,958 Of Predictive Oncology Inc [POAI]

    Chairman Raymond F. Vennare of Predictive Oncology Inc filed a Form 4 with the SEC, disclosing changes in ownership. On November 28, 2025, he exercised 8,331 shares and surrendered 2,373 shares at $5.90 each to cover option exercise costs and tax liabilities, ending with 6,418 shares directly.

    Reuters·
    US
    POAI
    0.00%
    US
    AGPU
    0.00%
    Reuters·
    US
    POAI
    0.00%
    US
    AGPU
    0.00%

    Predictive Oncology Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement

    Dec 2 (Reuters) - Predictive Oncology Inc:* PREDICTIVE ONCOLOGY REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM STOCKHOLDERS' EQUITY REQUIREMENT Source text: Further company coverage:

    Reuters·
    US
    POAI
    0.00%
    Reuters·
    US
    POAI
    0.00%
    © 2025 Longbridge｜Disclaimer